These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27193863)

  • 1. Anti-Microtubule Drugs.
    Florian S; Mitchison TJ
    Methods Mol Biol; 2016; 1413():403-21. PubMed ID: 27193863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microtubule dynamics as a target in oncology.
    Risinger AL; Giles FJ; Mooberry SL
    Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
    Li L; Jiang S; Li X; Liu Y; Su J; Chen J
    Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubulins - the target for anticancer therapy.
    Vindya NG; Sharma N; Yadav M; Ethiraj KR
    Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses.
    Barasoain I; García-Carril AM; Matesanz R; Maccari G; Trigili C; Mori M; Shi JZ; Fang WS; Andreu JM; Botta M; Díaz JF
    Chem Biol; 2010 Mar; 17(3):243-53. PubMed ID: 20338516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
    Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
    Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of small molecule inhibitors that interact with γ-tubulin.
    Friesen DE; Barakat KH; Semenchenko V; Perez-Pineiro R; Fenske BW; Mane J; Wishart DS; Tuszynski JA
    Chem Biol Drug Des; 2012 May; 79(5):639-52. PubMed ID: 22268380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
    Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
    FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-tubulin cytotoxic agents for breast cancer.
    Morris PG; Fornier MN
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):175-85. PubMed ID: 19192956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
    Churchill CD; Klobukowski M; Tuszynski JA
    Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
    Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
    Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Microtubule polymerization inhibitors].
    Takahata T; Sato A; Saito K; Yamagata K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():162-6. PubMed ID: 25831744
    [No Abstract]   [Full Text] [Related]  

  • 19. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
    Jordan A; Hadfield JA; Lawrence NJ; McGown AT
    Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microtubule drugs: action, selectivity, and resistance across the kingdoms of life.
    Dostál V; Libusová L
    Protoplasma; 2014 Sep; 251(5):991-1005. PubMed ID: 24652407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.